Navigation Links
Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
Date:2/1/2008

WALTHAM, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will release financial results for the fourth quarter and fiscal year ended December 31, 2007 on Wednesday, February 6, 2008 prior to the opening of the U.S. financial markets. A conference call will be held at 8:30 a.m. Eastern Time with Steven Rauscher, President and CEO, and other members of Oscient's management team. The Company announced preliminary revenue results of approximately $80 million for fiscal year 2007 on January 14, 2008.

What: Fourth Quarter and Fiscal Year 2007 Financial Results

When: February 6, 2008 at 8:30 am Eastern Time

How: Domestic participants can access the call by dialing

1-888-634-4009.

International participants are asked to dial 1-706-634-5451. The call

will also be webcast through the Company's website at

http://www.oscient.com.

Contact: Christopher Taylor, 781-398-2466 or Sarah Emond, 781-398-2544

A replay will be available two hours after the conclusion of the call until February 13, 2008. Domestic participants can access the replay by dialing 1-800-642-1687, while international participants are asked to dial 1-706-645-9291. The conference ID number for the replay is 33514080. A replay will also be available through http://www.oscient.com.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States; ANTARA(R) (fenofibrate) capsules, a cardiovascular product and FACTIVE(R) (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient promotes ANTARA and FACTIVE through a nationwide sales force calling on primary care physicians, cardiologists, endocrinologists and pulmonologists. The Company also has a novel, late-stage antibiotic candidate, Ramoplanin, for the treatment of Clostridium difficile-associated disease (CDAD).

For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at http://www.antararx.com and http://www.factive.com. For a complete description of the risks associated with our business please refer to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2007 and in other filings that we may make with the Securities and Exchange Commission from time to time.


'/>"/>
SOURCE Oscient Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
2. Webcast Alert: HCA Announces 4Q-Year End 07 Earnings Report
3. Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast
4. CBIZ Webcasts Fourth-Quarter and Year-End 2007 Conference Call
5. RESMED to Webcast Second Quarter 2008 Earnings Conference Call
6. Coherent, Inc. to Webcast First Fiscal Quarter 2008 Results
7. Moog Inc. Announces First Quarter 2008 Earnings Webcast on January 25, 2008
8. BD Announces Webcast of Annual Meeting of Shareholders
9. PPD Announces Fourth Quarter and Year-End 2007 Earnings Release, Webcast and Conference Call
10. Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results
11. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: